MET and non-small cell lung carcinoma: NSCLC-harboring MET alterations are sensitive to treatment with inhibitors such as crizotinib and cabozantinib, and the therapeutic effect of these drugs is proportionally correlated with the levels of amplification; indeed, patients with higher levels of MET amplification are also expected to have longer progression-free survival (PFS) [105,110].